DNTH Stock Forecast & Price Target

Dianthus Therapeutics is viewed favorably because its lead asset, claseprubart, is advancing with the Phase 2 MoMeNtum MMN readout on track for 4Q26 and already exceeding its original 36-patient target with 46 patients enrolled, while the trial’s design focuses on safety in a roughly 10,000-patient U.S. market. The company’s broader pipeline adds upside through DNTH312, an internally developed bifunctional fusion protein that showed strong preclinical complement and Ig reductions and a longer half-life than a comparator, with a clinical program planned by YE27. Financially, the $1.2B cash position provides runway beyond pivotal readouts, supporting continued development across classeprubart, DNTH212, and DNTH312 despite higher operating expenses and a 12% discount rate.

Dianthus Therapeutics is a clinical-stage biotech with no commercial revenue base, making its valuation dependent on the success of a single pipeline asset and future regulatory outcomes rather than recurring product sales. Its latest results underscore that fragility, with 2Q26 revenue of just $761K and a $0.90 diluted loss per share, while 2026 is projected to bring no revenue in 2H26 and a $3.87 diluted loss per share. Although it held about $887M in cash and short-term equivalents and expects runway into 2030, the need for additional studies, uncertain approval requirements, and likely future capital market reliance create meaningful execution and dilution risk.